Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | 0.43% | 203.20 | 1.2% | $410.88m | |
| GILD | Gilead Sciences, Inc. | 0.29% | 73.88 | 0.9% | $388.27m | |
| CELG | Celgene Corporation | -0.26% | 87.38 | 1.2% | $331.13m | |
| BIIB | Biogen Inc. | 0.60% | 338.91 | 1.2% | $285.04m | |
| ILMN | Illumina, Inc. | -0.15% | 350.37 | 3.5% | $238.24m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.19% | 383.70 | 2.6% | $211.99m | |
| EXAS | Exact Sciences Corporation | 1.90% | 74.14 | 25.3% | $196.59m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -0.29% | 176.60 | 1.9% | $158.10m | |
| SRPT | Sarepta Therapeutics, Inc. | -1.06% | 151.95 | 16.4% | $124.69m | |
| A | Agilent Technologies, Inc. | 0.93% | 69.57 | 1.5% | $120.73m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.95% | 121.97 | 2.0% | $110.07m | |
| VKTX | Viking Therapeutics, Inc. | 0.98% | 19.65 | 0.9% | $100.12m | |
| NKTR | Nektar Therapeutics | -2.81% | 56.69 | 5.6% | $93.69m | |
| ALNY | Alnylam Pharmaceuticals, Inc | 1.14% | 94.82 | 9.7% | $93.23m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.21% | 99.77 | 4.4% | $92.72m |
Company Profile
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant. It also develops Anti-C3 CB 2782 for dry age-related macular degeneration. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.